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A Potent Tartrate Resistant Acid 
Phosphatase Inhibitor to Study 
the Function of TRAP in Alveolar 
Macrophages
Carian E. Boorsma1,8, T. Anienke van der Veen1,8, Kurnia S. S. Putri2, Andreia de Almeida3, 
Christina Draijer1,8, Thais Mauad4, Gyorgy Fejer5, Corry-Anke Brandsma6,8, Maarten van den 
Berge7,8, Yohan Bossé  9, Don Sin10,11, Ke Hao12, Anja Reithmeier13, Göran Andersson13, Peter 
Olinga2, Wim Timens  6,8, Angela Casini1,3 & Barbro N. Melgert  1,8
The enzyme tartrate resistant acid phosphatase (TRAP, two isoforms 5a and 5b) is highly expressed in 
alveolar macrophages, but its function there is unclear and potent selective inhibitors of TRAP are required 
to assess functional aspects of the protein. We found higher TRAP activity/expression in lungs of patients 
with chronic obstructive pulmonary disease (COPD) and asthma compared to controls and more TRAP 
activity in lungs of mice with experimental COPD or asthma. Stimuli related to asthma and/or COPD 
were tested for their capacity to induce TRAP. Receptor activator of NF-κb ligand (RANKL) and Xanthine/
Xanthine Oxidase induced TRAP mRNA expression in mouse macrophages, but only RANKL also induced 
TRAP activity in mouse lung slices. Several Au(III) coordination compounds were tested for their ability 
to inhibit TRAP activity and [Au(4,4′-dimethoxy-2,2′-bipyridine)Cl2][PF6] (AubipyOMe) was found to be 
the most potent inhibitor of TRAP5a and 5b activity reported to date (IC50 1.3 and 1.8 μM respectively). 
AubipyOMe also inhibited TRAP activity in murine macrophage and human lung tissue extracts. 
In a functional assay with physiological TRAP substrate osteopontin, AubipyOMe inhibited mouse 
macrophage migration over osteopontin-coated membranes. In conclusion, higher TRAP expression/
activity are associated with COPD and asthma and TRAP is involved in regulating macrophage migration.
Tartrate resistant acid phosphatase (TRAP) is a metalloenzyme and a member of the purple acid phosphatases, 
containing a binuclear iron (Fe3+/Fe2+) center that facilitates the hydrolysis of phosphate esters and the genera-
tion of reactive oxygen species (ROS)1–5. It is highly expressed in osteoclasts and alveolar macrophages and lower 
expression can be found in activated macrophages and dendritic cells6–9.
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TRAP exists in two isoforms: the 5a isoform is a monomer, while the 5b isoform is a dimer derived from 5a 
by proteolytic cleavage of a repressive loop domain and is the enzymatically more active form1,10–12. Alveolar 
macrophages have especially high expression of TRAP5a while osteoclasts express high levels of TRAP5b6,7,13. The 
function of TRAP5b in bone has been studied in relation to bone remodeling extensively, in which TRAP activity 
was found to mediate osteoclast migration2,14,15. Osteoclasts are attached to bone matrix through an osteopon-
tin - integrin alphav-beta3 (αvβ3) bond. Migration of osteoclasts is promoted when this bond is disconnected by 
TRAP-dependent dephosphorylation of osteopontin.
The role of TRAP5a in alveolar macrophages has not been clarified yet but it has been postulated to play a 
role in bacterial killing by its ability to generate ROS16. In addition, little is known about the regulation of TRAP 
expression in alveolar macrophages. Two studies investigated the expression of TRAP in lung tissue and another 
specifically measured TRAP expression in alveolar macrophages and all found higher expression in smokers17–19. 
Therefore, we investigated whether its expression and/or activity are also altered in patients with chronic obstruc-
tive pulmonary disease (COPD) and other obstructive respiratory diseases like asthma and which disease-specific 
conditions can change TRAP expression/activity.
Exploring the function of TRAP activity in the lung has been hampered by the availability of only few inhib-
itors that either have low potency, low stability or are toxic15,20–24. Hayman et al. demonstrated potent inhibitory 
effects of sodium tetrachloroaurate (NaAuCl4) on TRAP activity20. However, this Au(III) complex is a reactive 
compound prone to reduction in biological environment and has unspecific protein binding, which may interfere 
with many different cellular pathways. In recent years, gold-based compounds of different families have been 
shown to possess ideal enzyme/protein inhibition properties, which allow them to be designed and exploited 
as chemical probes to study protein functions in biological systems and to possibly be developed as therapeutic 
agents25–28. Thus, a series of gold coordination complexes with N-donor ligands, conferring stability to Au(III) 
ions, were screened for TRAP inhibition in vitro. Among the newly tested gold complexes, the compound 
[Au(4,4′-dimethoxy-2,2′-bipyridine)Cl2][PF6] (AubipyOMe, Fig. 1) was found to be the most potent inhibitor of 
TRAP activity described to date.
We subsequently used AubipyOMe to study the function of TRAP in macrophages. Our starting hypothesis 
was that TRAP activity is also involved in regulation of osteopontin-dependent macrophage migration, similar to 
osteoclasts in bone. Osteopontin is expressed on the luminal side of epithelial cells and alveolar macrophages are 
present in the lumen of airways and alveoli29. Alveolar macrophages also express αvβ3 integrins and we hypothe-
sized that they may also need TRAP to migrate30. Therefore, we used AubipyOMe to investigate functional aspects 
of TRAP activity in macrophages, such as cell migration.
Results
TRAP expression is higher in smokers and in patients with COPD. To assess whether TRAP mRNA 
expression is changed in COPD versus control lung tissue, we did a single gene look-up for TRAP in a genome 
wide gene expression dataset comparing 311 COPD patients and 270 non-COPD controls31. Among the upregu-
lated genes, TRAP was identified as significantly higher in COPD patients compared to control patients (Fig. 2a). 
To investigate the effect of current smoking on TRAP expression, we additionally compared control individuals 
currently smoking with individuals that had stopped smoking for at least 5 years in the same dataset. This com-
parison showed significantly higher expression of TRAP in the individuals that are currently smoking versus 
ex-smokers (Fig. 2b). A similar analysis among the COPD patients showed no differences between current and 
ex-smokers (data not shown).
In addition, we examined whether TRAP mRNA expression correlated with lung function in COPD patients 
(as defined by FEV1) and found a significant but weak negative correlation, meaning higher TRAP expression was 
linked with lower FEV1 values (Fig. 2c). This correlation is mainly caused by the high expression of TRAP in lung 
tissue of patients with severe COPD: patients with the most severe disease, i.e. highest GOLD stage and therefore 
lowest FEV1 value, had significantly higher expression of TRAP in lung tissue as compared to nonCOPD con-
trols, while the patients with less severe COPD had similar TRAP expression as compared to controls (Fig. 2d).
Patients dying of asthma have more TRAP-active macrophages in lung tissue. To assess whether 
asthma is also characterized by changes in TRAP, we investigated the number of cells staining positive for TRAP 
Figure 1. Chemical structure of the Au(III) compound [Au(4,4′-dimethoxy-2,2′-bipyridine)Cl2][PF6] 
(AubipyOMe).
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activity in lung sections of patients who had died from an asthma attack or had died of non-pulmonary causes. 
The sections showed that only alveolar macrophages stained positive for active TRAP enzyme, as judged by their 
morphology and location in the tissue, though not all alveolar macrophages were positive for TRAP activity 
(Fig. 3a and b, some are indicated by arrows). In addition, the number of macrophages positive for TRAP activity 
was higher in lung tissue from patients with fatal asthma as compared to control subjects (Fig. 3c).
The number of TRAP-active cells is higher in mouse models for COPD and asthma. To check if 
higher expression/activity of TRAP in humans with pulmonary disease was a general phenomenon that could be 
extrapolated to mouse models, we examined TRAP activity in lungs of mice exposed to either cigarette smoke 
for 9 months (COPD model) or house dust mite (HDM) for 2 weeks (asthma model). Again, we stained for 
active TRAP enzyme and found that alveolar macrophages, as judged by their morphology and location in the 
tissue, stained strongly positive for active TRAP enzyme, though not all of them were positive for TRAP activity 
(Fig. 4a,b,d,e, some are indicated by arrows). In lung tissue of mice that were exposed to cigarette smoke (Fig. 4c 
or HDM (Fig. 4f) we found significantly more TRAP-positive macrophages than in lung tissue of the relevant 
control mice. In lung tissue of HDM-exposed mice faint staining for active TRAP enzyme could also be noticed 
in inflammatory infiltrates and in epithelial cells of the large airways (Fig. 4e).
TRAP expression is upregulated by RANKL and oxidative stress. In order to study what causes 
the higher activity and/or expression of TRAP in alveolar macrophages, we exposed murine MPI alveolar-like 
Figure 2. High TRAP expression is associated with COPD. (a) TRAP mRNA expression was significantly 
higher in lung tissue of patients with COPD (n = 311) than in their respective controls (n = 270). (b) TRAP 
mRNA expression was significantly higher in lung tissue of current smoking control individuals (n = 73) than in 
control exsmokers after at least 5 years of smoking cessation (n = 106). (c) TRAP mRNA expression correlated 
negatively with lung function (FEV1). (d) TRAP mRNA expression was only significantly higher in lung tissue 
of patients with severe COPD (GOLD stage IV) compared to control individuals, and not in patients with 
less severe COPD compared to the controls. Differences between 2 groups were tested with a Mann-Whitney 
U test, between multiple groups with a Kruskal-Wallis test with a Dunn’s correction for multiple testing. The 
correlation between TRAP mRNA expression and FEV1 was calculated using a Spearman correlation test. A p 
value smaller than 0.05 was considered significant.
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macrophages (Max Planck Institute, a kind gift from Dr. Gyorgy Fejer32) and murine precision-cut lung slices to 
various stimuli related to COPD and asthma, namely IL-4, M-CSF and RANKL, the damage-associated molecular 
pattern ATP, and oxidative stress mimicked by the xanthine/xanthine oxidase (X/XO) system. Notably, TRAP 
mRNA expression in MPI alveolar-like macrophages was significantly higher after stimulation with RANKL and 
the X/XO system (Fig. 5A). M-CSF stimulation resulted in a trend towards lower TRAP mRNA expression. No 
significant effects were observed after stimulation with ATP or IL-4.
Figure 3. More TRAP-active macrophages are associated with fatal asthma. (a) Representative pictures 
of lung tissue sections of a control individual stained for TRAP activity. Cells positive for TRAP activity 
(purple) are alveolar macrophages as judged by morphology and tissue location (some indicated by arrows). 
(b) Representative pictures of lung tissue sections of a fatal asthma patient stained for TRAP activity. (c) 
Quantification of the stainings showed that parenchymal lung tissue of patients with fatal asthma (n = 10) 
contained more TRAP-active macrophages as compared to controls dying of nonpulmonary causes (n = 8). 
Differences were tested using a Mann-Whitney U test. A p value smaller than 0.05 was considered significant.
www.nature.com/scientificreports/
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To study whether changes in mRNA expression would also lead to changes in active enzyme, we used 
precision-cut lung slices to study the effects of RANKL, ATP and oxidative stress on TRAP activity (Fig. 5B). Only 
RANKL treatment resulted in significantly higher TRAP activity in lung slices as compared to control conditions. 
Conversely, ATP treatment and induction of oxidative stress with X/XO treatment did not lead to significant 
changes in TRAP activity.
The Au(III) compound AubipyOMe inhibits TRAP activity. Having a potent and specific inhibitor 
of TRAP can greatly benefit studies into its function, and we therefore investigated whether we could improve 
on the currently known inhibitors of TRAP15,20–24. The most potent inhibitor previously reported is the inor-
ganic complex NaAuCl420, but this Au(III) reactive compound is prone to reduction in biological environments 
and features unspecific protein binding and oxidative damage, which may interfere with many different cellular 
pathways33. Therefore, a series of gold coordination compounds, more stable in biological environments com-
pared to NaAuCl4, were evaluated as possible TRAP activity inhibitors: these included mono- and di-nuclear 
Au(III) compounds with N-donor ligands and the previously tested anti-rheumatic agent sodium aurothiomalate 
(Myochrysine®, see Supplementary Fig. S1 for the structures of the compounds tested)20. The initial screening 
using commercially bought recombinant TRAP revealed that the compound AubipyOMe possessed the best 
TRAP inhibition activity described to date, similar to NaAuCl4, being able to inhibit the protein activity with IC50 
in the nanomolar range (see Supplementary Fig. S2 for inhibition curves of all compounds tested).
Thus, we continued our investigations with AubipyOMe, and NaAuCl4 as reference compound, to further 
assess its selectivity for the TRAP isoforms 5a and 5b. AubipyOMe inhibited TRAP5a activity with an IC50 value 
of 1.3 ± 0.5 μM and TRAP5b with an IC50 value of 1.8 ± 0.3 μM (Fig. 6a and b). These IC50 values were compara-
ble to the values found for NaAuCl4 (see Table 1 and Supplementary Fig. S3 for the individually fitted curves used 
to calculate IC50 values). To assess the inhibition potencies in more relevant biological settings, we continued 
testing AubipyOMe and NaAuCl4, in cell and tissue lysates. TRAP activity in cell lysates of MPI alveolar mac-
rophages was significantly inhibited in the presence of AubipyOMe and NaAuCl4 with IC50 values of 1.7 ± 0.4 μM 
and 0.7±0.0 μM, respectively (Fig. 6c, Table 1, and Supplementary Fig. S3 for the individually fitted curves used to 
Figure 4. High TRAP activity is associated with exposure to smoke and house dust mite. (a,b) Representative 
pictures of lung tissue sections of an air-exposed control mouse and a smoke-exposed mouse stained for TRAP 
activity. Alveolar macrophages stained strongly positive for TRAP (purple) as indicated by the arrows. (c) 
Quantification of the stainings showed that parenchymal lung tissue of mice exposed to cigarette smoke for 
9 months (n = 5) contained more TRAP-active alveolar macrophages than mice exposed to room air (n = 6). 
(d,e) Representative pictures of lung tissue sections of a control mouse and a house dust mite-exposed mouse 
stained for TRAP activity. Alveolar macrophages stained strongly positive for TRAP (purple) as indicated by 
the arrows. In lung tissue of HDM-exposed mice faint staining for active TRAP enzyme could also be noticed in 
inflammatory infiltrates and in epithelial cells of the large airways (f) Quantification of the stainings showed that 
mice exposed to HDM (n = 8) had more TRAP+ alveolar macrophages in parenchymal lung tissue than control 
mice (n = 8). Differences were tested using a Mann-Whitney U test. A p value smaller than 0.05 was considered 
significant.
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calculate IC50 values). Importantly, the inhibitory effects of AubipyOMe and NaAuCl4 were also tested on TRAP 
activity in pooled lung tissue lysates from COPD patients. AubipyOMe significantly inhibited TRAP activity 
in these lysates with an IC50 value of 4.8 ± 1.3 μM, while NaAuCl4 inhibited the activity with an IC50 value of 
3.6 ± 0.0 μM (Fig. 6d, table, and Supplementary Fig. S3 for the individually fitted curves used to calculate IC50 
values). At concentrations around these IC50 values, both AubipyOMe and NaAuCl4 had no cytotoxic effects on 
RAW264.7 macrophages (Fig. 6e). Only in very high concentrations AubipyOMe showed some cytotoxicity (IC50 
around 35 μM) and NaAuCl4 did not display significant toxicity (IC50 > 200 μM).
Macrophage migration depends on TRAP activity and is inhibited by AubipyOMe. Osteoclast 
migration was previously shown to be TRAP-dependent through the ability of TRAP to dephosphorylate osteo-
pontin2,14. To investigate if this is also the case for macrophages we used RAW264.7 macrophages because we 
could modulate TRAP expression and activity from low to high by pretreatment with RANKL in these cells34. We 
subsequently investigated the effects of having TRAP activity and inhibition of this TRAP activity on macrophage 
migration in a transwell and live cell-imaging setup (Fig. 7).
RAW264.7 macrophages pretreated with RANKL for 72 hours migrated significantly more through an 
osteopontin-coated membrane as compared to unstimulated cells (Fig. 7a). This effect was osteopontin-specific, 
as migration over a membrane coated with collagen was not affected by RANKL pretreatment (Fig. 7b). RANKL 
pretreatment and the presence of our proposed TRAP inhibitor AubipyOMe led to significantly less migration of 
RAW264.7 macrophages as compared to RANKL pretreatment alone. Accordingly, the presence of the previously 
published TRAP-inhibitor 5-PNA, that inhibits TRAP-dependent migration of TRAP-overexpressing cancer cells 
also inhibited macrophage migration induced by RANKL pretreatment15. Treatment of the cells with either inhib-
itors alone did not affect macrophage migration and neither did AubipyOMe affect migration when cells were 
grown on collagen-coated membranes, indicating that the inhibition was not unspecific (Fig. 7).
Furthermore, we investigated the involvement of TRAP in macrophage migration using live cell imaging. 
RAW264.7 macrophages plated on wells coated with osteopontin showed more migratory behavior after RANKL 
pretreatment than control cells not pretreated with RANKL (Fig. 7c, movie 1 versus 2 in supplementary infor-
mation). The observed increased migratory behavior was not recorded when RANKL-pretreated cells were in 
the presence of AubipyOMe (Fig. 7c, movie 3, supplementary information). The presence of AubipyOMe did not 
affect the migratory behavior of control cells (Fig. 7c, movie 4, supplementary information).
For both the transwell migration experiments as well as the live cell imaging, pretreatment with RANKL for 
48–72 hours did not lead to the development of multinucleated osteoclast-like cells. This can also be appreciated 
from the images in Fig. 7c and the movies in the supplementary information available.
Discussion
A distinct characteristic of alveolar macrophages is the high expression of TRAP, yet the function of this enzyme 
in the lung is unclear. We first set out to investigate whether the presence of TRAP is changed in obstructive 
pulmonary diseases to see if it has any relevance to these disease processes. We observed higher TRAP expres-
sion in COPD and asthma as compared to control and we found that this increase may be triggered by RANKL 
and/or oxidative stress, though the functional consequences of this higher expression and activity remain to be 
determined. To aid the elucidation of the role of TRAP in the lung, we developed a new type of TRAP-inhibitor: 
Figure 5. RANKL and oxidative stress are inducers of TRAP. (A) TRAP mRNA expression in murine MPI 
alveolar macrophages was significantly higher after stimulation with 200 ng/ml RANKL (n = 10) for 24 h or 16 
h of exposure to xanthine/xanthine oxidase (n = 7) to mimic oxidative stress as compared to control conditions 
(n = 10). Exposure to 10 ng/ml M-CSF (n = 10) for 24 hrs resulted in a trend towards downregulation of TRAP 
mRNA expression. 10μg/ml ATP (n = 10) and 10 ng/ml IL-4 (n = 9) had no effect on TRAP mRNA expression. 
(B) TRAP activity was higher in precision-cut murine lung slices incubated with 200 ng/ml RANKL (n = 6) 
for 24 hrs as compared to slices incubated in control conditions (n = 6). No effect on TRAP activity was seen 
following stimulation with 10μg/ml ATP (n = 6) or xanthine/xanthine oxidase (n = 6) for 24 hrs. Differences 
between the multiple groups were tested with a Kruskal-Wallis test with a Dunn’s correction for multiple testing. 
A p value smaller than 0.05 was considered significant.
www.nature.com/scientificreports/
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AubipyOMe. This Au(III)-based compound is the most potent inhibitor of the phosphatase function of TRAP 
described to date and was used here to show that TRAP appears to be involved in macrophage migration.
To the best of our knowledge, TRAP expression levels have never been studied before in relation to COPD. 
Only three studies have looked at the effect of smoking, the most important risk factor of COPD, and found 
elevated TRAP mRNA and/or protein expression in smokers17–19. Our results confirm these previous findings 
for current smoking and we now also show that, TRAP mRNA expression is higher in lung tissue of COPD 
patients compared with controls, independent of smoking status. Since TRAP mRNA expression is higher with 
Figure 6. AubipyOMe is a potent TRAP inhibitor. (a) Activity of recombinant TRAP5a was inhibited by 
NaAuCl4 (IC50: 1.4 ± 0.2 μM) and AubipyOMe (IC50: 1.3 ± 0.5 μM) (n = 3). (b) Activity of recombinant 
TRAP5b was inhibited by NaAuCl4 (IC50: 1.0 ± 0.2 μM) and AubipyOMe (IC50: 1.8 ± 0.3 μM) (n = 3). (c) 
TRAP activity in lysates of murine MPI alveolar macrophages was inhibited by NaAuCl4 (IC50: 0.7 ± 0.0 μM) 
and AubipyOMe (IC50: 1.7 ± 0.4 μM) (n = 3). (d) TRAP activity in lysates from lung tissue of COPD patients 
was inhibited by NaAuCl4 (IC50: 4.8 ± 1.3 μM) and AubipyOMe (IC50: 3.6 ± 0.0 μM) (n = 3). (e) Incubation of 
RAW264.7 macrophages with AubipyOMe only inhibits cell viability at concentrations far exceeding the IC50 
value, NaAuCl4 did not have any toxicity (n = 4).
Compounds
IC50 (µM)
TRAP5a TRAP5b MPI COPD
NaAuCl4 1.4 ± 0.2 1.0 ± 0.2 0.7 ± 0.0 4.8 ± 1.3
AubipyOMe 1.3 ± 0.5 1.8 ± 0.3 1.7 ± 0.4 3.6 ± 0.0
Table 1. Effect of AubipyOMe and NaAuCl4 on TRAP activity (data are represented as mean ± standard error).
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the highest disease severity, a disease-specific factor may be causing the increase in TRAP expression on top of 
smoking-related induction of TRAP.
TRAP has not been studied in the context of asthma. This chronic lung disease has a different pathogenesis 
from COPD but we now show that it is also characterized by higher numbers of TRAP-active macrophages in 
lung tissue as compared to controls. Hence, we investigated some overlapping cytokines and conditions of both 
obstructive lung diseases to identify the cause of the high TRAP expression/activity in these lung diseases. In 
vitro experiments showed that the most likely candidate to induce TRAP expression/activity is RANKL. RANKL 
is a well-known inducer of TRAP expression in osteoclasts (multinuclear bone macrophages) and was included 
as a positive control. However, higher levels of RANKL have also shown to be present in patients with COPD, 
especially those suffering from osteoporosis, a well-known comorbidity of emphysematous COPD35,36. Therefore, 
the high levels of circulating RANKL may explain the high TRAP expression and activity in lung tissue of COPD 
patients. Our data showing that especially GOLD stage IV patients, transplanted for severe emphysema, have the 
highest mRNA expression of TRAP are in line with this observation. To the best of our knowledge, no reports 
have been published about the levels of RANKL in (fatal) asthma patients and it therefore remains unclear 
whether and how RANKL could play a role in (fatal) asthma.
Our results also showed that TRAP mRNA expression is higher in macrophages cultured under 
high-oxidative-stress conditions. Indeed, oxidative stress is a known inducer of osteoclast formation accompa-
nied by increased TRAP5b expression in these cells37,38. Patients with COPD have been shown to have high levels 
of oxidative and nitrosative stress in their lungs and in asthma basal oxidative stress levels are elevated as a result 
of chronic inflammation39–42. This oxidative stress may therefore be responsible for elevated macrophage TRAP 
Figure 7. TRAP is involved in macrophage migration. (a) In a transwell set-up, RANKL-stimulated RAW264.7 
macrophages (200 ng/ml) for 72 h migrated significantly more through an osteopontin-coated membrane as 
compared to control macrophages. This RANKL-induced migration was not seen in the presence of our newly 
proposed TRAP inhibitor AubipyOMe (80 nM) or in the presence of previously published TRAP inhibitor 
5-PNA (100 μM). Both inhibitors did not affect migration on their own. Data represent seven independent 
experiments. Differences between the multiple groups were tested with a Kruskal-Wallis test with a Dunn’s 
correction for multiple testing. A p value smaller than 0.05 was considered significant (b) Using collagen-coated 
membranes, no differences were found in transwell migration when RAW264.7 macrophages were stimulated 
with RANKL (200 ng/ml) or not and no effect of TRAP inhibitor AubipyOMe (80 nM) on migration was 
found. Data represent six independent experiments. Differences between the multiple groups were tested with 
a Kruskal-Wallis test with a Dunn’s correction for multiple testing. A p value smaller than 0.05 was considered 
significant (c) Live cell tracking of macrophages in osteopontin-coated wells revealed that macrophage 
migratory behavior was higher in the presence of RANKL (200 ng/ml) as compared to control and AubipyOMe 
(80 nM) inhibited this migratory behavior (movies can be found in the online supplementary information, 
Movies 1–4).
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mRNA expression. Interestingly, the higher TRAP expression following oxidative stress in macrophages in vitro 
did not result in higher TRAP activity in lung slices that were cultured under similar conditions. The reason for 
this conflicting result is unclear but may relate to the activity assay not being sensitive enough to pick up differ-
ences in lung slices or to the slicing and subsequent incubation of lung tissue, leading to abnormal consumption 
of reducing agents like glutathione in the tissue that are necessary for optimal TRAP activity43,44.
TRAP itself may also contribute to oxidative stress levels in the lung through its oxygen radical producing 
potential44. In fact, alveolar macrophages are an important first-line defense against pathogens and their TRAP 
expression was shown to contribute to ROS formation and bacterial killing3,16,45,46. The monomeric, intracellular 
TRAP5a isoform can generate cellular oxidative stress through oxidation of one of the iron atoms in its active 
site3. High TRAP expression/activity in COPD and asthma may therefore contribute to the increased levels of 
oxidative stress found in these diseases39–42.
To further aid investigations into the function of (elevated) TRAP activity in alveolar macrophages, we iden-
tified Au(III)-containing compounds as potent inhibitors of TRAP, with AubipyOMe as the most active one 
described to date15,20–24. It should be noted that this compound (and analogues) has previously been tested for its 
reactivity with other proteins, but the inhibitory effects were extremely moderate compared to those shown here 
for the TRAP isoforms47,48. Interestingly, in contrast to the other previously characterized inhibitor 5-PNA that 
only inhibits TRAP5b, AubipyOMe could inhibit both isoforms to a similar extent15. Docking studies combined 
to molecular modeling will have to elucidate which parts of the molecules are responsible for the differential 
effects. These results are an excellent basis for further rational design of compounds with high affinity and high 
inhibition potential of TRAP and its specific isoforms.
To test our inhibitor in a physiological setting with a physiological substrate we investigated whether TRAP 
could be involved in migration of macrophages by dephosphorylation of osteopontin as has been reported before 
for osteoclasts and cancer cells2,14,15,49,50. Extracellular TRAP5b activity was shown to contribute to osteoclast 
migration by dephosphorylation of osteopontin thereby reducing (αvβ3-integrin-mediated) cell adhesion of oste-
oclasts. We now show that TRAP activity in macrophages has a similar function, because upregulation of TRAP 
by RANKL stimulation resulted in more macrophage migration over an osteopontin-coated membrane. In addi-
tion, subsequent inhibition of TRAP activity by AubipyOMe, as well as the previously reported TRAP-inhibitor 
5-PNA, resulted in less macrophage migration, implying a similar mode of action of these two inhibitory com-
pounds. As 5-PNA only inhibits TRAP5b, the observed migratory behavior is likely to be dependent on this 
isoform.
Functional consequences of enhanced macrophage migration in lung tissue in diseases like COPD and asthma 
remain to be investigated. Work of the group of Väänänen et al. showed that TRAP is involved in matrix degrad-
ing processes by assisting in trafficking of collagens in vesicles through the cell and that TRAP colocalized with 
phagocytosed material within alveolar macrophages16,51. Therefore, alveolar macrophage TRAP may participate 
in the tissue remodeling processes that play a role in both asthma and COPD.
Another possible role for TRAP in COPD and asthma could be the regulation of interferon alpha (IFNα) pro-
duction. Both COPD and asthma are characterized by exacerbations, often induced by viral infections52. IFNα 
is important in defenses against viruses and Briggs et al. recently showed that TRAP inhibits IFNα production 
by regulating intracellular levels of phosphorylated osteopontin in dendritic cells53. Expression of nonfunctional 
TRAP led to higher levels of IFNα and therefore high expression of TRAP (like in COPD and asthma) may 
result in a lower IFNα production. Indeed, lower levels of IFNα have been detected in patients with asthma and 
COPD54,55. Based on these considerations, the gold-based TRAP inhibitor AubipyOMe could be used to investi-
gate the role of TRAP in IFNα production by alveolar macrophages.
An unexpected outcome was the clear downregulation of TRAP expression in alveolar-like macrophages after 
M-CSF stimulation. In the bone field, previous studies have shown that M-CSF is necessary for osteoclast forma-
tion and TRAP expression56, but exposure to high levels of M-CSF early during differentiation may actually blunt 
differentiation into osteoclasts and therefore TRAP expression57,58. A similar mechanism may be in play here. In 
addition, this discrepancy in M-CSF responsiveness may be caused by the fact that we used alveolar-like mac-
rophages, which are derived from fetal monocytes/yolk sac macrophages and self-maintain in lung tissue during 
life, while osteoclasts are derived from hematopoietic stem cells and are replenished from bone marrow59–63. 
Since alveolar macrophages are particularly dependent on GM-CSF for their development, this could explain the 
discrepancy in the response to M-CSF61.
In conclusion, TRAP expression and activity are high in COPD and fatal asthma and in relevant mouse mod-
els. One of the roles of TRAP may be to facilitate macrophage migration, but the consequences of this for the 
pathogenesis of COPD and asthma are still unclear. The development of our potent gold-based TRAP inhibitor 
now allows more detailed studies into the function of TRAP in the lung and diseases of the lung characterized by 
higher TRAP activity such as asthma and COPD.
Materials and Methods
All methods were carried out in accordance with relevant national and local guidelines and regulations regarding 
the use of experimental animals, tissues of human subjects and proper research conduct. More detailed informa-
tion for each part is available in the online supplementary information “Material and Methods” section.
Human tissue. COPD. Gene expression data of TRAP was obtained from a large gene expression study 
comparing lung tissue from 311 patients with COPD and 270 non-COPD controls that were part of the Lung 
eQTL consortium. Details of this population can be found in Supplementary Table S1. All lung tissue samples 
were obtained in accordance with Institutional Review Board guidelines at the three sites: Laval University 
(Quebec, Canada), University of British-Columbia (Vancouver, Canada) and Groningen University (Groningen, 
The Netherlands). All patients provided written informed consent and the study was approved by the ethics 
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committees of the Institut universitaire de cardiologie et de pneumologie de Québec and the UBC-Providence 
Health Care Research Institute Ethics Board for Laval and UBC, respectively. The study protocol was consistent 
with the Research Code of the University Medical Center Groningen and Dutch national ethical and professional 
guidelines (“Code of conduct; Dutch federation of biomedical scientific societies”; http://www.federa.org). A 
detailed description of the whole genome mRNA profiling has been previously published by Brandsma et al. and 
Hao et al.31,64.
Asthma. Post mortem lung tissues from subjects with fatal asthma or subjects who died from nonpulmonary 
causes (controls) were retrieved from the Department of Pathology of São Paulo University (São Paulo, Brazil). 
Patient characteristics can be found in Supplementary Table S2. A detailed clinical and demographic description 
of this population has been previously published by Mauad et al.65. Diagnosis was confirmed by macro- and 
microscopic examination at autopsy and by an interview with the next of kin. Written informed consent was 
obtained with the next of kin. All experimental protocols within this study were approved by the institutional 
ethics committee Comissão de Ética para Análise de Projetos de Pesquisa - CAPPesq do Hospital das Clínicas, 
São Paulo University Medical School and were carried out in accordance with their guidelines. For this study we 
investigated the presence of TRAP activity in paraffin-embedded peripheral lung tissue samples of 10 asthma 
patients and 8 controls as described below.
Animal experiments. During the experiments, all animals were held under specific pathogen-free condi-
tions in groups of 4–6 mice per cage in a temperature-controlled room with a 12h dark/light cycle and permanent 
access to food and water. The Groningen University Institutional Animal Care and Use Committee approved 
these experiments according to strict governmental and international guidelines on animal experimentation 
(DEC2857, DEC5318, and DEC6416AA-001).
Smoke-induced lung inflammation. To model COPD, we exposed five male A/JOlaHsd mice (Harlan, Horst The 
Netherlands, 8–10 weeks old) nose-only to mainstream cigarette smoke for 9 months in an experimental set-up 
as described before by us66. Mice were sacrificed after 9 months and lungs were collected, formalin-fixed and 
embedded in paraffin for histological analysis of TRAP activity.
Allergic lung inflammation. To model asthma, we exposed male and female BALB/c mice (Harlan, Horst The 
Netherlands, 8–10 weeks old) intranasally to whole body house dust mite (HDM) extract (Dermatophagoides 
pteronyssinus, Greer laboratories, Lenoir, USA) in 40 μl phosphate-buffered saline (PBS) according to a protocol 
we have described before67. Mice were sacrificed on day 24 and lungs were collected for histological analyses and 
TRAP activity analyses. Other parameters of allergic lung inflammation of these animals are described in detail 
in our previous publication67.
Enzyme histochemistry for TRAP activity. Presence of active TRAP was assessed using a histochemical 
method relying on conversion of chromogen Fast Red by active TRAP (see online supplement). The number of 
positive alveolar macrophages (based on morphology and tissue location) was counted manually with the aid of 
ImageScope software (Leica Biosystems, Son, The Netherlands) in human and murine lung tissue sections (on 
average a surface of 9 mm2 was measured of each section) and corrected for the surface area of the corresponding 
lung tissue.
Cell culture of macrophages. Self-propagating murine alveolar-like macrophages (MPI macrophages, a 
kind gift from dr. G. Fejer, Plymouth University, Devon, UK) were cultured in RPMI 1640 medium (Gibco, 
Bleiswijk, The Netherlands) as described by Fejer et al.32. Cells were stimulated with a superoxide-generating 
system (0.2 mM Xanthine + 10 mU/ml Xanthine oxidase (Sigma-Aldrich, Zwijndrecht, The Netherlands)) for 
16 hrs to mimic oxidative stress, or for 24 hrs with the damage-associated molecular pattern ATP (1, 10 or 100 μg/
ml, Sigma-Aldrich), RANKL (200 ng/ml, produced and provided by dr. R.H. Cool, University of Groningen, The 
Netherlands68), IL-4 (10 ng/ml, Peprotech, Rocky Hill, USA), or M-CSF (10 ng/ml, Peprotech). Cells were har-
vested for mRNA isolation purposes.
RAW264.7 macrophages (American Type Culture Collection) were cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen, The Netherlands). RAW264.7 macrophages were used in transwell and cell-tracking exper-
iments, as further explained in the section “Inhibition of macrophage migration by AubipyOMe”.
Quantitative Real-Time PCR. The fol lowing primers were used to determine TRAP 
mRNA expression, Primers used for RT-PCR were obtained from Sigma-Aldrich: TRAP forward: 
5′-GCTGTCCTGGCTCAAAAAGC-3′; TRAP reverse: 5′-CACACCGTTCTCGTCCTGAA-3′; GAPDH forward: 
5′-ACAGTCCATGCCATCACTGC-3′; GAPDH reverse: 5′-GATCCACGACGGACACATTG-3′. For each sam-
ple, the threshold cycles (Ct values) were calculated with the SDS 2.3 software program (Applied Biosystems) and 
mRNA expression was normalized against GAPDH. Experiments were repeated at least four times.
Precision-cut lung slices. Lungs of male C57BL/6 mice (20–30 gr) of in total six mice were used to make 
precision-cut lung slices. Lung slices, diameter 5-mm and weight ± 5 mg, were prepared with a Krumdieck tissue 
slicer (Alabama Research and Development, Munford, USA) as described by us before for liver slices69. After 
slicing, murine lung slices were transferred to 12-well plates with pre-warmed DMEM + Glutamax medium (1.3 
ml + supplements) and incubated in triplicate with the following stimulants: vehicle, RANKL (200 ng/ml), ATP 
(10 μg/ml), or Xanthine (0.2 mM) + Xanthine oxidase (10 mU/ml). Three slices of each condition were pooled 
and used to measure TRAP activity.
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TRAP activity assay on lysates of MPI macrophages and precision-cut lung slices. TRAP activ-
ity levels were determined in lung slice homogenates or MPI macrophage lysates by incubation at 37 °C for 1 
hour with an L-para-Nitrophenylphosphate (PNPP) solution [100 mM PNPP, 200 mM sodium citrate, 200 mM 
sodium chloride, 80 mM sodium tartrate, pH 4.5] at a 1:1 ratio. Absorption at 410 nm, with 490 nm as a reference 
value, was measured using a spectrophotometer. Each sample was measured in duplicate and stimulus outcome 
was calculated relative to the nonstimulated control absorption level.
Recombinant TRAP preparations and proteolytic digestion of TRAP. Recombinant unspecified 
human TRAP was purchased from R&D (Minneapolis, USA). Recombinant human TRAP5a and 5b were pro-
duced and purified according to a protocol based on several sources70–72 using an ÄKTApurifier™ 10 FPLC sys-
tem (GE Healthcare, Danderyd, Sweden) as previously described15.
Identification of TRAP inhibitors. Initially, a small library of gold compounds was tested for TRAP inhi-
bition using a TRAP activity assay with recombinant unspecified human TRAP (R&D). The Au(III) compounds 
[Au(terpy)Cl]Cl2 (terpy = terpyridine, Auterpy), [Au2(μ-O)2(bipy)2](PF6)2 (bipy = 2,2′-bipyridine, Auoxo) 
and [Au(bipyOMe)Cl2][PF6] (bipyOMe = 4,4′-dimethoxy-2,2′-bipyridine, AubipyOMe) were synthesized as 
previously described and their purity was confirmed by elemental analysis and showed to be >98%47,73,74. The 
anti-rheumatic Au(I) compound sodium aurothiomalate and the reference Au(III) complex NaAuCl4 were pur-
chased from Sigma-Aldrich.
Inhibitor dilutions were prepared in acetate buffer from freshly prepared stock solutions (10 mM in DMSO). 
Recombinant unspecified TRAP (1.25 ng/ml, pH 4.5), TRAP5a (150 ng/mL, pH 5) or TRAP5b (150 ng/mL, pH 
5.8) were incubated at 37 °C for 30 minutes with PNPP solution [10 mM PNPP, 200 mM sodium acetaat, 300 mM 
potassium chloride) at the indicated pH at a 1:1 ratio and increasing concentrations of NaAuCl4 (range 0–40 μM) 
or Au compounds (range 0–5.1 μM). To stop the reaction, 1M NaOH was added and absorption at 410 nm, with 
490 nm as a reference value, was measured using a spectrophotometer.
Testing of inhibitors on cell and tissue lysates. Mouse alveolar macrophage lysates were obtained by resuspending 
500.000 MPI macrophages in 300 μl acetate buffer. Human lung lysates from COPD patients were used to test 
the inhibitor on human TRAP present in lung tissue. Lysates from in total 18 COPD patients were pooled (see 
Supplementary Table S3 for patient characteristics).
AubipyOMe was tested in the range 0–40 μM with MPI cell lysates or pooled lung tissue lysates from COPD 
patients using a TRAP activity assay. Lysates were incubated at 37 °C for 30 min in the presence of PNPP solution 
(1:1 ratio). 1M NaOH was added to stop the reaction and absorption was measured at 410 nm with 490 nm as a 
reference value.
IC50 calculations. The inhibitory effects of gold compounds were calculated as the ratio of absorbance 
between the treated and untreated wells. The IC50 values were calculated using nonlinear curve fitting with a 
variable slope in Graphpad Prism 6 (Graphpad Software, la Jolla, USA). An average IC50 of three independent 
experiments was calculated.
MTT assay. The effect of AubipyOMe and NaAuCl4 on RAW264.7 cell growth was assessed with a classical 
MTT assay. The IC50 values were calculated using nonlinear curve fitting with a variable slope in Graphpad Prism 
6 (Graphpad Software) An average IC50 of four independent experiments was calculated.
Transwell experiment to assess macrophage migration. Migration of RAW264.7 macrophages was assessed using 
a transwell-culturing system with inserts (Sigma-Aldrich) coated with osteopontin (10 μg/ml, R&D). Bovine 
collagen-coated inserts (10 μg/ml, Advanced Biometrix, Carlsbad, USA) were used as matrix control. Cells were 
incubated with or without RANKL (200 ng/ml) for 72 hours to induce TRAP activity or not75, in the presence or 
absence of AubipyOMe (80 nM) in quadruplicate. The previously described TRAP inhibitor 5-PNA (100 μM) was 
used as selective positive control for TRAP inhibition15,23. The number of cells migrated to the lower well, includ-
ing dead cells, was calculated relative to control cells and individual experiments were done at least six times.
Confocal imaging of macrophage migration. Briefly, RAW264.7 macrophages were plated on osteopontin-coated 
(10 μg/ml, R&D) Lab-tek chamber slides (Nunc, Hatfield, USA). Cells were incubated with or without RANKL 
(200 ng/ml) for 48 hours to induce TRAP activity or not75, followed by labeling with carboxyfluorescein diacetate 
succinimidyl ester (CFSE, Invitrogen, Life Technologies Europe BV, Bleiswijk, The Netherlands) to visualize cells 
for live cell imaging using a confocal microscope (Solamere Nipkow Confocal Live Cell Imaging system, Solamere 
Technology Group, Salt lake city, USA). Cell movement was tracked overnight in the presence of 1% zymosan 
solution (Sigma-Aldrich), to stimulate cell movement, and with or without TRAP inhibitor AubipyOMe (80 nM). 
Pictures were taken every 10 min and were transformed into movies with Image J and Imaris x64 (Bitplane, 
Zurich, Switzerland) software76.
Statistical analysis. All data were assumed to have nonnormal distributions. Statistical differences between 
two groups were calculated using a Mann-Whitney U test. When comparing multiple groups, a Kruskal-Wallis 
with a Dunn’s correction for multiple testing was performed. When studying correlations, a Spearman coefficient 
was calculated to test for significant relationships. P < 0.05 was considered significant for all data. Statistical tests 
were done using Graphpad Prism 6 (Graphpad Software). Data are presented as Box and Whiskers plots with the 
whiskers representing the 2.5–97.5 percentile.
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Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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